sharesgurusharesguru
  • Stocks
  • Ai Screener
  • Sectors
  • Watchlist
LoginSign Up
sharesguru
  • Home
  • Stocks
  • Ai Screener
  • Sectors
  • Watchlist
  • Profile
  • Contact Us
LoginSign Up
sharesguru

Discover the joy of investing.

All the financial data and tools you need, at one place.

Navigation

  • Home
  • Stocks
  • Sectors

Tools

  • Ai Screener
  • Watchlists

Company

  • Contact

Legal

  • Privacy Policy
  • Terms of Service
Copyright © 2025 Knowtilus Technologies Pvt. Ltd.
SummaryLatest NewsSector ComparisonEarnings ReportRevenue & GrowthPeersIncome StatementBalance SheetCash Flow
CAMLINFINE logo

CAMLINFINE - Camlin Fine Sciences Ltd Share Price

Chemicals & Petrochemicals
Sharesguru Stock Score

CAMLINFINE

41/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹123.09-3.06(-2.43%)
Market Open as of Jul 14, 2026, 15:29 IST
Pros

Balance Sheet: Reasonably good balance sheet.

Cons

Technicals: SharesGuru indicator is Bearish.

Dividend: Stock hasn't been paying any dividend.

Dilution: Company has a tendency to dilute it's stock investors.

Momentum: Stock has a weak negative price momentum.

Past Returns: Underperforming stock! In past three years, the stock has provided -6.8% return compared to 7.6% by NIFTY 50.

Smart Money: Smart money is losing interest in the stock.

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Sharesguru Stock Score

CAMLINFINE

41/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

Valuation

Market Cap2.47 kCr
Price/Earnings (Trailing)92.47
Price/Sales (Trailing)1.37
EV/EBITDA27.48
Price/Free Cashflow100.76
MarketCap/EBT-63.09
Enterprise Value3.03 kCr

Fundamentals

Revenue (TTM)1.81 kCr
Rev. Growth (Yr)0.40%
Earnings (TTM)23.54 Cr
Earnings Growth (Yr)78.33%

Profitability

Operating Margin-1%
EBT Margin-2%
Return on Equity2.35%
Return on Assets1.01%
Free Cashflow Yield0.99%

Growth & Returns

Price Change 1W-6%
Price Change 1M0.90%
Price Change 6M-15.9%
Price Change 1Y-56.2%
3Y Cumulative Return-6.8%
5Y Cumulative Return-9.1%
7Y Cumulative Return12%
10Y Cumulative Return3%

Cash Flow & Liquidity

Cash Flow from Investing (TTM)-52.95 Cr
Cash Flow from Operations (TTM)82.07 Cr
Cash Flow from Financing (TTM)-24.63 Cr
Cash & Equivalents108.56 Cr
Free Cash Flow (TTM)24.5 Cr
Free Cash Flow/Share (TTM)1.28

Balance Sheet

Total Assets2.32 kCr
Total Liabilities1.32 kCr
Shareholder Equity1 kCr
Current Assets1.23 kCr
Current Liabilities974.42 Cr
Net PPE625.09 Cr
Inventory503.74 Cr
Goodwill233.41 Cr

Capital Structure & Leverage

Debt Ratio0.29
Debt/Equity0.67
Interest Coverage-1.51
Interest/Cashflow Ops2.08

Dividend & Shareholder Returns

Shares Dilution (1Y)2.2%
Shares Dilution (3Y)22.3%
Pros

Balance Sheet: Reasonably good balance sheet.

Cons

Technicals: SharesGuru indicator is Bearish.

Dividend: Stock hasn't been paying any dividend.

Dilution: Company has a tendency to dilute it's stock investors.

Momentum: Stock has a weak negative price momentum.

Past Returns: Underperforming stock! In past three years, the stock has provided -6.8% return compared to 7.6% by NIFTY 50.

Smart Money: Smart money is losing interest in the stock.

The Good, Bad and Ugly
Growth
Measures how quickly a company is expanding through metrics like revenue growth, earnings growth, and cash flow growth over time. Strong growth can indicate future potential.
Profitability
Shows how efficiently a company turns business activities into profit, using metrics like profit margins, return on equity (ROE), and return on assets (ROA).
Size
Indicates the company's market presence through metrics like market capitalization, total assets, and revenue. Size can influence stability and market influence.
Dilution Rank
Tracks how much the company's shares have increased or decreased over time. Lower dilution means existing shareholders maintain stronger ownership stakes.
Balance Sheet
Evaluates the company's financial health by analyzing assets, debts, and equity. A strong balance sheet indicates financial stability and flexibility.
Momentum
Measures the strength and speed of price movements, showing whether the stock is gaining or losing market favor over different time periods.
Technicals
Analyzes price patterns, trading volumes, and other market indicators to identify potential trading opportunities and market trends.
Smart Money
Tracks the investment activities of institutional investors, hedge funds, and other large financial players who often have deep research capabilities.
Insider Trading
Monitors buying and selling of company shares by executives, directors, and other insiders who may have unique insights into the company's prospects.

Investor Care

Shares Dilution (1Y)2.2%
Earnings/Share (TTM)1.39

Financial Health

Current Ratio1.27
Debt/Equity0.67

Technical Indicators

RSI (14d)32.7
RSI (5d)20.16
RSI (21d)50.96
MACD SignalSell
Stochastic Oscillator SignalBuy
SharesGuru SignalSell
RSI SignalHold
RSI5 SignalBuy
RSI21 SignalHold
SMA 5 SignalSell
SMA 10 SignalSell
SMA 20 SignalSell
SMA 50 SignalSell
SMA 100 SignalSell

Summary of Latest Earnings Report from Camlin Fine Sciences

Summary of Camlin Fine Sciences's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Management provided an optimistic outlook regarding future performance, especially in the Vanillin segment. For fiscal year 2027 (FY'27), the company anticipates a total sales volume of 4,000 metric tons of Vanillin, a significant increase from the 1,740 metric tons sold in the first nine months of FY'26. They expect Vanillin realizations to improve to around $14-$14.5 per kg, which is reflective of a 25% tariff reduction.

In terms of financial performance, management projected that overall revenue for the company would reach approximately Rs.2,200 crores in FY'27 and further increase to Rs.2,400 crores in FY'28. They projected EBITDA margins to improve between 12% to 14%, driven by enhanced sales volumes and realizations in the Vanillin segment along with 20%-25% growth in the Blends business.

Key forward-looking points emphasized include:

  1. A 25% reduction in tariffs is expected to boost Vanillin realizations significantly, allowing for improved margins.
  2. The integration of acquisitions like Vinpai is expected to positively influence revenue growth, where the company anticipates up to 50% growth in the blended business segments next year.
  3. The immediate focus is on minimizing losses from a recent fire incident at the Brazil facility, where stock worth approximately Rs.28 crores was lost. While they are adequately insured, there may be temporary margin impacts due to local sourcing needed to fulfill orders.
  4. An anticipated clean-up from the liquidation processes in Europe could stabilize costs and halt ongoing cash burns.

Overall, management seems confident in maintaining growth trajectories while managing transitioning challenges.

1. Question from Hrushikesh Shah: "Sir, my first question is currently our Vanillin realization at $12, right? And you mentioned that they may increase by $2 to $3. So, according to me, let's say your realization in the US is $18. If your tariffs move down by 25%, then your realization should increase by $6. So, where is the disconnect in this?"
Answer: The price in the US is around $18-$19, which is correct. However, we had to pay 50% duty to realize $12. With the duty reduced to 25%, our realization will improve to about $14-$14.5. This adjustment accounts for local competition without the duty.

2. Question from Hrushikesh Shah: "What is the volume guidance for FY'27?"
Answer: For FY'27, we expect total Vanillin sales, including methyl and ethyl, to be around 4,000 metric tons.

3. Question from Hrushikesh Shah: "What was the revenue for Vinpai for the full year?"
Answer: Vinpai's consolidated revenue has been around Rs. 13 crores monthly, so the annual turnover is approximately Rs. 150 crores.

4. Question from Hrushikesh Shah: "What do you think is our steady-state margin?"
Answer: Our steady-state gross margin should improve to 46%-47% in FY'27 due to increased Vanillin realizations and growth in the blends business. The EBITDA margin is expected to range between 12%-14%.

5. Question from Satish Kumar: "What is the duty right now in the US?"
Answer: The current duty is 25%. Once the trade deal is finalized, we expect this to drop to 18%.

6. Question from Satish Kumar: "What was the quantity of Vanillin we did not sell this quarter?"
Answer: We opted to delay the sale of about 200 tons to benefit from the lower duty in the next quarter, aiming for a better realization.

7. Question from Surya Narayan Patra: "Will Vanillin pricing in the US affect Europe too post-tariff?"
Answer: No, there will be a disparity. The anti-dumping duties in Europe are much higher, meaning pricing dynamics will remain different between the US and Europe.

8. Question from Surya Narayan Patra: "What is the impact of the Brazilian fire incident?"
Answer: While the blending unit is temporarily closed, the incident will not significantly impact our top-line revenue. However, we may face margin pressure short-term due to local sourcing.

9. Question from Rehan: "What would be the margin profile at EBITDA level for Vinpai and the other acquisitions?"
Answer: Vinpai is currently near breakeven with minimal EBITDA contribution, while Vitafor is stable with margins around 4%-12%.

10. Question from Rohan Advant: "What is the revenue guidance for '27 and '28?"
Answer: We are targeting around Rs. 2,200 crores for FY'27, growing to approximately Rs. 2,400 crores in FY'28, assuming current product pricing remains steady.

Share Holdings

Understand Camlin Fine Sciences ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Share Holding Details

Shareholder NameHolding %
Ashish Subhash Dandekar10.3%
Infinity Direct Holdings10.18%
Anfima Nv8.83%
Infinity Holdings6.2%
Infinity Direct Capital4.82%
Icici Prudential Commodities Fund4.8%
Camart Finance Limited2.77%
Nirmal Vinod Momaya1.88%
Franklin India Opportunites Fund1.69%
Anagha Subhash Dandekar1.57%
Vibha Agencies Pvt Ltd1.36%
Ajay Upadhyaya1.3%
Infinity Portfolio Holdings1.17%
Jagdish N Master1%
Cafco Consultants Limited0.78%
Radha Pandit0.04%
Anand Y Pandit0.01%
MK Falcon Agro tech Pvt. Ltd.0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Camlin Fine Sciences Better than it's peers?

Detailed comparison of Camlin Fine Sciences against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker
Name
Mkt Cap
Revenue
Price %, 1M
Returns, 1Y
P/E
P/S
Rev 1-Yr
Inc 1-Yr
VINATIORGAVinati Organics13.83 kCr2.28 kCr+2.40%-30.80%31.176.07--
SEQUENTSequent Scientific12.08 kCr2.68 kCr+9.60%+46.90%85.114.51--
JUBLINGREAJubilant Ingrevia11.5 kCr4.43 kCr+17.50%-9.30%41.062.6--
BALAMINESBalaji Amines7.82 kCr1.45 kCr+13.30%+28.50%46.555.38--
GALAXYSURFGalaxy Surfactants7.09 kCr5.27 kCr+16.60%-21.90%26.531.35--

Sector Comparison: CAMLINFINE vs Chemicals & Petrochemicals

Comprehensive comparison against sector averages

Comparative Metrics

CAMLINFINE metrics compared to Chemicals

CategoryCAMLINFINEChemicals
PE92.4746.52
PS1.374.40
Growth5.3 %6.2 %
33% metrics above sector average
Key Insights
  • 1. CAMLINFINE is NOT among the Top 10 largest companies in Specialty Chemicals.
  • 2. The company holds a market share of 1.2% in Specialty Chemicals.
  • 3. The company is growing at an average growth rate of other Specialty Chemicals companies.

Income Statement for Camlin Fine Sciences

Consolidated figures (in Rs. Crores) /
Description(%) Q/QMar-2026Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Revenue From Operations3.4%1,7231,6671,6131,6821,4121,187
Other Income115.4%2914165.8334.98
Total Income4.2%1,7521,6811,6291,6871,4451,192
Cost of Materials4.7%823786747856728488
Purchases of stock-in-trade-24.8%89118114614578
Employee Expense27.2%244192179163145120
Finance costs-27.3%7310060583638
Depreciation and Amortization11.1%716479635644
Other expenses7.9%450417447500355301
Total Expenses8.5%1,7601,6221,6781,5971,3511,087
Profit Before exceptional items and Tax-115.8%-8.1959-49.449094105
Exceptional items before tax-144.5%-25.46-9.82-49.8-9.6800
Total profit before tax-172.2%-33.6549-99.248094105
Current tax-58.5%184225293227
Deferred tax55%-18.38-42.06-19.24121.5312
Total tax-57%-0.460.075.63413440
Total profit (loss) for period114.5%24-158.12-104.88406065
Other comp. income net of taxes118.4%3.44-12.231820-7.77114
Total Comprehensive Income115.2%27-170.35-86.916053179
Earnings Per Share, Basic105.1%1.46-8.03-5.583.454.654.13
Earnings Per Share, Diluted104.7%1.42-7.94-5.53.414.563.68
Debt equity ratio--0.720-00
Debt service coverage ratio--0.010-00
Description(%) Q/QMar-2026Dec-2025Sep-2025Jun-2025Mar-2025Dec-2024
Revenue From Operations-7%425457460424437433
Other Income1085.6%242.944.598.569.591.34
Total Income-2.4%449460464432447435
Cost of Materials-55.1%121268209226195173
Purchases of stock-in-trade30.8%181432172.3645
Employee Expense3.2%666460605052
Finance costs29.4%231819161634
Depreciation and Amortization25%211719171814
Other expenses-3.3%119123119108113116
Total Expenses-4.9%447470464437413433
Profit Before exceptional items and Tax102.7%1.3-10.090.27-5.15341.52
Exceptional items before tax51.6%-7.95-17.5100-5.590
Total profit before tax73.3%-6.65-27.60.27-5.15291.52
Current tax-73%1.924.415.615.98144.32
Deferred tax-70.6%-8.16-4.370.3-5.99-6.042.82
Total tax-662.1%-6.240.055.91-0.017.957.14
Total profit (loss) for period323.1%86-37.1-14.95-10.680.11-7.47
Other comp. income net of taxes-481.4%-11.894.38-0.98125.79-12.11
Total Comprehensive Income316.5%74-32.72-15.931.255.9-19.58
Earnings Per Share, Basic223.4%4.59-1.91-0.76-0.53-0.04-0.243
Earnings Per Share, Diluted221.6%4.54-1.91-0.76-0.52-0.04-0.24
Debt equity ratio-----0.72-
Debt service coverage ratio-----0.01-
Standalone figures (in Rs. Crores) /
Description(%) Q/QMar-2026Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Revenue From Operations-5.4%838886773789686600
Other Income70%35211929195.47
Total Income-3.8%873907792818704606
Cost of Materials-25.5%402539426403382384
Purchases of stock-in-trade-83.2%3.69178.465.547.6216
Employee Expense5.6%767266605339
Finance costs1.5%676654573333
Depreciation and Amortization1.9%545349332719
Other expenses2.3%268262237236161121
Total Expenses-2.6%911935850752668590
Profit Before exceptional items and Tax-36.5%-37.82-27.43-57.7673616
Exceptional items before tax82.2%-16.27-96-1.9300-0.5
Total profit before tax55.7%-54.09-123.43-59.63673615
Current tax-251.5%01.660146.42.78
Deferred tax55.5%-21.13-48.78-8.245.153.813.96
Total tax54%-21.13-47.12-8.2419106.74
Total profit (loss) for period56.1%-32.97-76.31-51.3948268.28
Other comp. income net of taxes-270.1%-4.7-0.54-0.04-0.66-0.15-0.38
Total Comprehensive Income50.3%-37.66-76.85-51.4347267.9
Earnings Per Share, Basic49.4%-1.74-4.41-3.093.181.980.67
Earnings Per Share, Diluted48.9%-1.74-4.36-3.053.141.940.6
Debt equity ratio-0.5%00510000
Debt service coverage ratio-0.8%00770000
Description(%) Q/QMar-2026Dec-2025Sep-2025Jun-2025Mar-2025Dec-2024
Revenue From Operations-16.1%184219244191273205
Other Income193.5%155.77103.69106.82
Total Income-11.6%199225254195283212
Cost of Materials-30%7811111499150106
Purchases of stock-in-trade647.4%2.040.810.370.470.580.48
Employee Expense-10.5%182019191917
Finance costs50%221519111717
Depreciation and Amortization-7.7%131413131313
Other expenses-6.1%636772667470
Total Expenses-6.6%213228258212271219
Profit Before exceptional items and Tax-225.8%-14.02-3.61-3.81-16.3812-7.19
Exceptional items before tax75.4%-2.61-13.66000.260
Total profit before tax3.4%-16.64-17.27-3.81-16.3812-7.19
Current tax-000000
Deferred tax-127.5%-10.99-4.27-0.17-5.7-3.72-1.57
Total tax-127.5%-10.99-4.27-0.17-5.7-3.72-1.57
Total profit (loss) for period52.5%-5.65-13-3.64-10.6816-5.63
Other comp. income net of taxes-192.6%-0.990.32-4.250.221.94-2.32
Total Comprehensive Income44.1%-6.64-12.67-7.89-10.4618-7.95
Earnings Per Share, Basic23.7%-0.29-0.69-0.19-0.570.86-0.33
Earnings Per Share, Diluted23.7%-0.29-0.69-0.19-0.560.85-0.327
Debt equity ratio-0---051-
Debt service coverage ratio-0---077-

Balance Sheet for Camlin Fine Sciences

Consolidated figures (in Rs. Crores) /
Description(%) Q/QMar-2026Sep-2025Mar-2025Sep-2024Mar-2024Sep-2023
Cash and cash equivalents25.6%10987104808092
Current investments-102.6%04038000
Loans, current-111.1%010102.331010
Total current financial assets17.1%584499532415391358
Inventories-5.1%504531527501513591
Total current assets5.7%1,2341,1671,1831,0199991,047
Property, plant and equipment-0.8%625630593583757780
Capital work-in-progress128.6%33159.73224650
Investment property-186.2%02.162.16000
Goodwill404.3%2334747764753
Non-current investments3.6%302923237.887.88
Total non-current financial assets62.2%744637382222
Total non-current assets25%1,087870840864951965
Total assets14.1%2,3242,0372,0241,8851,9522,014
Borrowings, non-current4.5%303290268341333351
Total non-current financial liabilities8.7%337310294341350369
Provisions, non-current12.1%7.286.65.485.595.114.77
Total non-current liabilities9.1%349320303369362390
Borrowings, current3.7%365352377399325315
Total current financial liabilities15%950826817783690628
Provisions, current-32.5%9.11311109.589.45
Current tax liabilities-178%0.082.182.212.150.196.9
Total current liabilities13.8%974856846851732681
Total liabilities12.4%1,3231,1771,1491,2201,0951,071
Equity share capital0%191919171717
Non controlling interest-34.9%-40.07-29.45-26.89-24.47-7.8-0.76
Total equity16.4%1,001860875665857942
Total equity and liabilities14.1%2,3242,0372,0241,8851,9522,014
Standalone figures (in Rs. Crores) /
Description(%) Q/QMar-2026Sep-2025Mar-2025Sep-2024Mar-2024Sep-2023
Cash and cash equivalents218.2%3612360.230.680.14
Current investments-102.6%04038000
Loans, current-11.5%556259575243
Total current financial assets0.8%646641629471582564
Inventories-2%244249263252255281
Total current assets3.3%919890929748858864
Property, plant and equipment-3.8%514534520516560564
Capital work-in-progress83.3%23139.1243135
Investment property-186.2%02.162.16000
Non-current investments227.3%2176764648082
Loans, non-current-5.910004.6912
Total non-current financial assets208.3%2237367678898
Total non-current assets22%850697699706711724
Total assets11.7%1,7721,5871,6291,4561,5721,590
Borrowings, non-current11.8%210188172195222237
Total non-current financial liabilities9.8%214195182195237252
Provisions, non-current15.9%7.286.425.325.444.974.65
Total non-current liabilities10.5%222201187214249272
Borrowings, current19.8%261218270313269244
Total current financial liabilities14.7%608530567565580506
Provisions, current25%4.73.963.353.133.022.48
Current tax liabilities-0--0.0106.25
Total current liabilities14.8%621541580613607546
Total liabilities13.6%843742766826856818
Equity share capital0%191919171717
Total equity10.1%929844862630716772
Total equity and liabilities11.7%1,7721,5871,6291,4561,5721,590

Cash Flow for Camlin Fine Sciences

Consolidated figures (in Rs. Crores) /
Description(%) Q/QMar-2026Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Finance costs-18.2%82100605836-
Depreciation0%7474796356-
Impairment loss / reversal-171.7%-102.914609.680-
Unrealised forex losses/gains-189.4%-21.342637-8.88-16.96-
Adjustments for interest income-3.5301.230.731.56-
Share-based payments-1.9700.012.367.39-
Net Cashflows from Operations64.1%1066518771176-
Income taxes paid (refund)-37.8%2438482030-
Net Cashflows From Operating Activities211.5%822713951145-
Cashflows used in obtaining control of subsidiaries-000066-
Cash payment for investment in partnership firm or association of persons or LLP-103.3%031000-
Proceeds from sales of PPE-000.560.90-
Purchase of property, plant and equipment39%584261144214-
Dividends received-455.6%00.82000-
Interest received1507.1%2.970.861.230.731.7-
Other inflows (outflows) of cash753.5%34-4.05-7.712928-
Net Cashflows From Investing Activities29.3%-52.95-75.35-66.5-124.63-249.13-
Proceeds from issuing shares-100.5%02230095-
Proceeds from exercise of stock options43.2%0.540.190.580.550-
Proceeds from borrowings-6902581106-
Repayments of borrowings-77.1%17710-52.2730-
Payments of lease liabilities66.7%1610118.228.83-
Interest paid-13%6170735225-
Other inflows (outflows) of cash-00-28.13-13.85-0.71-
Net Cashflows from Financing Activities-136.1%-24.6372-85.9760136-
Net change in cash and cash eq.-84.9%4.4824-13.49-14.0732-
Standalone figures (in Rs. Crores) /
Description(%) Q/QMar-2026Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Finance costs1.5%6766545733-
Change in inventories-240-41.6700-
Depreciation1.9%5453493327-
Unrealised forex losses/gains-513.5%-22.96.786.68-19.23-5.75-
Adjustments for interest income-237%-6.156.224.744.14.11-
Share-based payments-1.25002.347.36-
Net Cashflows from Operations95.5%44231002648-
Income taxes paid (refund)-405%0.391.2187.391.15-
Net Cashflows From Operating Activities104.8%4422821947-
Cashflows used in obtaining control of subsidiaries-00006.55-
Cash payment for investment in partnership firm or association of persons or LLP-103.3%031000-
Proceeds from sales of PPE-1566.7%00.940.0800-
Purchase of property, plant and equipment22.7%282341131189-
Proceeds from sales of investment property-0.370000-
Interest received-1566.7%00.940.520.651.61-
Other inflows (outflows) of cash102%1.73-34.72-7.82928-
Net Cashflows From Investing Activities64.6%-30.4-87.66-51.72-114.73-172.33-
Proceeds from issuing shares-100.2%0.542230095-
Proceeds from exercise of stock options-000.580.550-
Proceeds from borrowings-3601412188-
Repayments of borrowings-97.6%2.44611.4021-
Payments of lease liabilities-1.2%7.657.7303.982.25-
Interest paid-26.4%4054473931-
Net Cashflows from Financing Activities-114.4%-13.41101-34.0578129-
Net change in cash and cash eq.-102.5%0.1535-3.67-17.823.39-

What does Camlin Fine Sciences Ltd do?

Specialty Chemicals•Chemicals•Small Cap
Industry Group:Chemicals & Petrochemicals
Employees:624
Website:www.camlinfs.com

Important Disclosure & Data Context

This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.

Performance Comparison

CAMLINFINE vs Chemicals (2021 - 2026)

CAMLINFINE is underperforming relative to the broader Chemicals sector and has declined by 69.5% compared to the previous year.